SCHEMBL438290

SCHEMBL438290

O=c1ccn(Br)c(=O)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5963506 0.70
SCHEMBL35355 0.70
SCHEMBL8377720 0.70
SCHEMBL8790967 0.70
SCHEMBL10423652 0.70
SCHEMBL21385228 0.70
SCHEMBL710129 0.70
SCHEMBL8377765 0.70 PKM (0.51)
SCHEMBL16632410 0.67 L3MBTL1 (0.53)
SCHEMBL21995599 0.67 CRBN (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4677085-A1 OLIGONUCLEOTIDE MODULATORS ACTIVATING FACTOR VII EXPRESSION AND USE THEREOF IN TREATMENT OF HEMOPHILIA Ractigen Therapeutics (CN) 2026-01-14 EP claimed
WO-2025201529-A1 COMPOUNDS FOR SYNTHESIZING MODIFIED SMALL ACTIVATING RNA MOLECULES, MODIFIED SMALL ACTIVATING RNA MOLECULES AND USES THEREOF RACTIGEN THERAPEUTICS (CN) 2025-10-02 WO claimed
WO-2024183714-A1 OLIGONUCLEOTIDE MODULATORS ACTIVATING FACTOR VII EXPRESSION AND USE THEREOF IN TREATMENT OF HEMOPHILIA RACTIGEN THERAPEUTICS (CN) 2024-09-12 WO claimed
CN-118546926-A Oligonucleotide molecules and their use in tumor therapy 中美瑞康核酸技术(南通)研究院有限公司 2024-08-27 CN claimed
CN-112912501-B Oligonucleotide molecules and their use in tumor therapy 中美瑞康核酸技术(南通)研究院有限公司 2024-07-16 CN claimed
CN-116848245-A Double-stranded nucleic acid molecules for the treatment of proliferative vitreoretinopathy and uses thereof 中美瑞康核酸技术(南通)研究院有限公司 2023-10-03 CN claimed
CN-116829716-A Chemically modified small activating RNA 中美瑞康核酸技术(南通)研究院有限公司 2023-09-29 CN claimed
CN-115916975-A Nucleic acid molecules targeting MITF genes and uses thereof 中美瑞康核酸技术(南通)研究院有限公司 2023-04-04 CN claimed
CN-114174511-A Oligomeric nucleic acid molecule for activating ATOH1 gene and application thereof 中美瑞康核酸技术(南通)研究院有限公司 2022-03-11 CN claimed
CN-110045048-B HPLC-MSMS method for determining concentrations of two antitumor drugs in human plasma 上海市第一人民医院 2021-07-06 CN claimed
WO-2008033432-A2 IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-03-20 WO claimed
EP-1372659-B1 SUBSTANCES FOR USE IN THERAPY OF DISEASES THAT ARE CAUSED BY HIGHLY PROLIFERATIVE CELLS SCHMALZ HANS GUENTHER (DE) 2004-07-28 EP claimed
US-20040116448-A1 Substances for the therapy of diseases caused by highly proliferating cells HANS-GUENTHER SCHMALZ (DE) 2004-06-17 US claimed
US-20040092468-A1 Immunostimulatory oligonucleotides with modified bases and methods of use thereof SCHWARTZ DAVID (US) 2004-05-13 US claimed
US-20040009602-A1 DNA modifying molecules and methods of use thereof THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES 2004-01-15 US claimed
EP-1121373-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF Dynavax Technologies Corporation (US) 2001-08-08 EP claimed
WO-1999024621-A9 METHODS AND COMPOSITIONS FOR DETECTION OF SPECIFIC NUCLEOTIDE SEQUENCES CYGENE INC (US) 2001-05-31 WO claimed
EP-1030936-A2 METHODS AND COMPOSITIONS FOR DETECTION OF SPECIFIC NUCLEOTIDE SEQUENCES Cygene, Inc. (US) 2000-08-30 EP claimed
WO-1999062923-A2 IMMUNOSTIMULATORY OLIGONUCLEOTIDES WITH MODIFIED BASES AND METHODS OF USE THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 1999-12-09 WO claimed
WO-1999024621-A2 METHODS AND COMPOSITIONS FOR DETECTION OF SPECIFIC NUCLEOTIDE SEQUENCES CYGENE, INC. (US) 1999-05-20 WO claimed